ArticleFrontiers in pharmacology2022

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).

M Karolyi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.